BlackRock-Backed Global Ports Deal Faces Uncertainty Amid Cosco Demands 
Nvidia and Groq Strike Strategic AI Inference Licensing Deal 
Nvidia to Acquire Groq in $20 Billion Deal to Boost AI Chip Dominance 
Hyundai Recalls Over 51,000 Vehicles in the U.S. Due to Fire Risk From Trailer Wiring Issue 
Novo Nordisk Stock Surges After FDA Approves Wegovy Pill for Weight Loss 
California DMV Proposes New Safety Rules for Autonomous Vehicles After Waymo Incidents 
Waymo Plans Safety and Emergency Response Upgrades After San Francisco Robotaxi Disruptions 
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccine Portfolio 
BP Nears $10 Billion Castrol Stake Sale to Stonepeak 
John Carreyrou Sues Major AI Firms Over Alleged Copyrighted Book Use in AI Training 
ByteDance Plans Massive AI Investment in 2026 to Close Gap With U.S. Tech Giants 
Texas App Store Age Verification Law Blocked by Federal Judge in First Amendment Ruling 
Mexico Antitrust Review of Viva Aerobus–Volaris Deal Signals Growth for Airline Sector 
FDA Approves Mitapivat for Anemia in Thalassemia Patients 
Nike Stock Jumps After Apple CEO Tim Cook Buys $2.9M Worth of Shares 
Saks Global Weighs Chapter 11 Bankruptcy Amid Debt Pressures and Luxury Retail Slowdown 
LOS ANGELES, Sept. 26, 2017 -- Lundin Law PC, a shareholder rights firm, announces a class action lawsuit against Teva Pharmaceutical Industries Limited (“Teva” or the “Company”) (NYSE:TEVA) regarding possible violations of federal securities laws from November 15, 2016 through August 2, 2017, inclusive (the “Class Period”). Investors who purchased or otherwise acquired Teva shares during the Class Period should contact the firm prior to October 23, 2017, the lead plaintiff motion deadline.
To participate in this class action lawsuit, click here.
You can also call Brian Lundin, Esq., of Lundin Law PC, at 888-713-1033, or you can e-mail him at [email protected].
No class has been certified in the above action yet. Until a class is certified, you are not considered represented by an attorney. You may also choose to do nothing and be an absent class member.
According to the Complaint, throughout the Class Period, Teva made false and/or misleading statements and/or failed to disclose that the poor performance of its U.S. generics business resulted in recording a goodwill impairment charge related to the acquisition of Actavis Generics and was a key factor in cutting the Company’s dividend by 75%. Upon this news, shares of Teva dropped in value materially, which caused investors harm according to the Complaint.
Lundin Law PC was founded by Brian Lundin, Esq., a securities litigator based in Los Angeles dedicated to upholding shareholders’ rights.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
Contact:
Lundin Law PC
Brian Lundin, Esq.
Telephone: 888-713-1033
Facsimile: 888-713-1125
[email protected]
http://lundinlawpc.com/
